GAM
ABBV icon

Grandview Asset Management’s AbbVie ABBV Stock Holding History

Grandview Asset Management’s Portfolio ABBV Stock Details ABBV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.53M Sell
17,987
-373
-2% -$80.2K 1.12% 21
2026
Q1 		$3.99M Sell
18,360
-364
-2% -$80.7K 1.17% 19
2025
Q4 		$4.28M Buy
18,724
+758
+4% +$173K 1.17% 18
2025
Q3 		$4.16M Sell
17,966
-73
-0.4% -$14.9K 1.17% 19
2025
Q2 		$3.35M Buy
18,039
+104
+0.6% +$19.3K 1.07% 22
2025
Q1 		$3.76M Buy
17,935
+85
+0.5% +$16.5K 1.43% 15
2024
Q4 		$3.17M Sell
17,850
-197
-1% -$36.2K 1.16% 19
2024
Q3 		$3.56M Sell
18,047
-168
-0.9% -$31.4K 2.04% 11
2024
Q2 		$3.12M Sell
18,215
-335
-2% -$55.5K 1.83% 14
2024
Q1 		$3.38M Sell
18,550
-300
-2% -$51.7K 1.53% 15
2023
Q4 		$2.92M Sell
18,850
-769
-4% -$112K 1.53% 15
2023
Q3 		$2.92M Sell
19,619
-1,489
-7% -$219K 1.68% 12
2023
Q2 		$2.84M Sell
21,108
-1,864
-8% -$273K 2.77% 11
2023
Q1 		$3.66M Sell
22,972
-2,304
-9% -$352K 2.15% 9
2022
Q4 		$4.08M Sell
25,276
-1,173
-4% -$180K 2.54% 9
2022
Q3 		$3.55M Sell
26,449
-1,181
-4% -$169K 2.26% 10
2022
Q2 		$4.23M Sell
27,630
-863
-3% -$132K 2.37% 9
2022
Q1 		$4.62M Sell
28,493
-541
-2% -$78.6K 1.95% 10
2021
Q4 		$3.93M Buy
29,034
+536
+2% +$63.3K 1.58% 12
2021
Q3 		$3.07M Sell
28,498
-192
-0.7% -$21.9K 3.16% 10
2021
Q2 		$3.23M Buy
28,690
+2,703
+10% +$304K 1.77% 15
2021
Q1 		$2.81M Sell
25,987
-206
-0.8% -$22K 1.5% 15
2020
Q4 		$2.81M Buy
26,193
+395
+2% +$38K 1.84% 12
2020
Q3 		$2.26M Sell
25,798
-1,296
-5% -$122K 1.83% 15
2020
Q2 		$2.66M Buy
+27,094
New +$2.39M 2.32% 9

Other funds holding ABBV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Grandview Asset Management's ABBV Position: Q2 2026 in Review

Grandview Asset Management reduced its AbbVie (ABBV) stake by 2% in Q2 2026, selling an estimated $80.2K and leaving 17,987 shares worth $4.53M. The position accounts for 1.12% of the portfolio, ranked #21.

Grandview Asset Management first reported a position in ABBV in Q2 2020 and has held it in 25 quarters since. The position peaked at $4.62M in Q1 2022. 4,194 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Grandview Asset Management held 17,987 shares of AbbVie worth $4.53M as of Q2 2026.
  • Grandview Asset Management sold 373 AbbVie shares in Q2 2026, an estimated $80.2K.
  • AbbVie made up 1.12% of Grandview Asset Management's portfolio in Q2 2026, its #21 holding.
  • Grandview Asset Management first reported a position in AbbVie in Q2 2020 and has held it in 25 quarters since.
  • Grandview Asset Management's AbbVie position peaked at $4.62M in Q1 2022.
  • 4,194 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Grandview Asset Management's 13F filing for Q2 2026, filed 24 Jul 2026.